Martin Haluzík on Residual Cardiovascular Risk in Coronary Artery Disease
Martin Haluzík, Professor of Medicine at Institute for Clinical and Experimental Medicine, shared on LinkedIn:
”Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Excellent review on residual cardiovascular risk in coronary artery disease just published in Nature Reviews Cardiology by Mattia Galli and colleagues.
Despite substantial advances in the secondary prevention of cardiovascular disease, atherosclerosis of the coronary arteries and its consequences remain the leading cause of death worldwide.
Residual cardiovascular risk refers to the ongoing risk of recurrent cardiovascular events that persists in patients with coronary artery disease despite receiving optimal secondary prevention treatment and effective control of conventional risk factors.
Lifestyle modification and therapies modulating thrombosis, blood pressure and LDL-cholesterol levels represent the standard approach for the prevention of recurrent cardiovascular events in patients with coronary artery disease.
However, current evidence-based therapies and lifestyle modification strategies only partially modulate the pathophysiological pathways involved in the progression and destabilization of atherosclerotic disease, and other mechanisms might have an important role, accounting, at least in part, for the residual cardiovascular risk in these patients.
In this Review, the authors appraise the available evidence and latest insights into the mechanisms and associated biomarkers of recurrent adverse cardiovascular events and provide perspectives on strategies to reduce residual cardiovascular risk in patients with coronary artery disease.
- Very well-written and comprehensive paper
- Great overview of traditional, emerging and novel CV risk markers
- Perfect description of subtypes of residual risks such as thrombotic, lipid, metabolic and inflammatory and the strategies for their mitigation
- Final subchapter on emerging factors such as exposome, microbiota and much more
A must read paper! Congratulations to the authors!”
Read the full article here.
Article: Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Authors: Mattia Galli, Antonio Abbate, Marc P. Bonaca, Filippo Crea, Maurizio Forte, Giacomo Frati, Mario Gaudino, C. Michael Gibson, Diana A. Gorog, Roxana Mehran, Rocco A. Montone, Michelle L. O’Donoghue, P. Gabriel Steg, Sebastiano Sciarretta, Dominick J. Angiolillo
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke